Cyttron II joined in the collective FES2009 application together with three other consortia: NIRM, Neurobasic and Virgo. DCTI was approved shortly thereafter. LSH was the central desk for these applications.
The Netherlands Institute for Regenerative Medicine (NIRM) combines cutting-edge research in stem cell biology with advances in tissue engineering, so as to improve existing and create novel regenerative medical treatments. Read more:
NeuroBasic-PharmaPhenomics wants to build new rodent models of neurological and psychiatric diseases and translate pre-clinical studies of animal models into novel treatments for human patients. Read more:
The mission of the VIRGO project is the rational design of vaccination and other intervention strategies for respiratory virus infections.
Read more: http://www.virgo.nl/
The mission of DCTI is to improve beta-cell replacement therapy and to make this therapy accessible for more patients with diabetes. The main research goals are to increase the availability of high quality islets for transplantation, identify factors for long-term islet function and survival, and to develop alternative transplantation sites with the use of biomaterials.
Read more: http://www.dcti.net/